靶向治疗时代议自身免疫病的感染挑战

doi:10.16150/j.1671-2870.2022.03.002

摘要/Abstract

中图分类号:

R593.2

李佳, 吕良敬. 靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303.

参考文献 25

[1]	Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs[J]. N Engl J Med, 2021, 385(7):628-639. doi: 10.1056/NEJMra1909094 URL
[2]	López-Benjume B, Rodríguez-Pintó I, Amigo MC, et al. Eculizumab use in catastrophic antiphospholipid syndrome(CAPS): Descriptive analysis from the "CAPS Re-gistry"[J]. Autoimmun Rev, 2022, 21(4):103055. doi: 10.1016/j.autrev.2022.103055 URL
[3]	Chandwar K. Avacopan for the treatment of ANCA-associated vasculitis[J]. N Engl J Med, 2021, 384(21):e81. doi: 10.1056/NEJMc2104672 URL
[4]	Azoulay E, Russell L, van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients[J]. Intensive Care Med, 2020, 46(2):298-314. doi: 10.1007/s00134-019-05906-5 pmid: 32034433
[5]	Bechman K, Halai K, Yates M, et al. Nonserious infections in patients with rheumatoid arthritis: results from the british society for rheumatology biologics register for rheumatoid arthritis[J]. Arthritis Rheumatol, 2021, 73(10):1800-1809. doi: 10.1002/art.41754 URL
[6]	Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry[J]. Ann Rheum Dis, 2010, 69(2):380-386. doi: 10.1136/ard.2008.089276 pmid: 19359261
[7]	Gottlieb AB, Deodhar A, Mcinnes IB, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data[J]. Acta Derm Venereol, 2022, 102:adv00698.
[8]	Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management[J]. Br J Dermatol, 2017, 177(1):47-62. doi: 10.1111/bjd.15015 pmid: 27580411
[9]	Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis[J]. N Engl J Med, 2010, 363(3):221-232. doi: 10.1056/NEJMoa0909905 URL
[10]	Iwata S, Saito K, Hirata S, et al. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus[J]. Lupus, 2018, 27(5):802-811. doi: 10.1177/0961203317749047 pmid: 29308726
[11]	国家神经疾病医学中心, 国家传染病医学中心, 上海市医学会神经内科专科分会, 等. 抗CD20单克隆抗体治疗神经免疫相关疾病期间感染管理上海专家建议(2022)[J]. 中国临床神经科学, 2022, 30(1):1-7.
	National Center for Neurological Disorders, National Medical Center for Infectious Diseases, Shanghai Medical Association Branch of Neurology, et al. Expert consensus on infection management for Anti-CD20 monoclonal antibody for the treatment of neuroimmune diseases(2022)[J]. Chin J Clin Neurosci, 2022, 30(1):1-7.
[12]	Md Yusof MY, Vital EM, McElvenny DM, et al. Predic-ting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases[J]. Arthritis Rheumatol, 2019, 71(11):1812-1823. doi: 10.1002/art.40937 URL
[13]	Konar M, Granoff DM. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults[J]. Blood, 2017, 130(7):891-899.
[14]	Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis[J]. Rheumatology (Oxford), 2019, 58(10):1755-1766. doi: 10.1093/rheumatology/kez087 pmid: 30982883
[15]	Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel di-seases or other immune-mediated diseases: a systematic review and meta-analysis[J]. Gastroenterology, 2020, 158(6):1554-1573,e12. doi: S0016-5085(20)30011-1 pmid: 31926171
[16]	Li J, Yu Y, Xie J, et al. Cryptococcal pneumonia in a patient with rheumatoid arthritis treated with baricitinib[J]. Rheumatology (Oxford), 2021, 61(1):e6-e7.
[17]	Valor-Méndez L, Voskens C, Rech J, et al. Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report[J]. Rheumatology (Oxford), 2021, 60(4):e122-e123.
[18]	Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases[J]. Ann Rheum Dis, 2020, 79(1):39-52. doi: 10.1136/annrheumdis-2019-215882 URL
[19]	Allen V, Longley N. Infections in immunosuppressed travellers with autoimmune inflammatory diseases-a narrative review and advice for clinical practice[J]. Rheumatology (Oxford), 2021, 60(9):3969-3976. doi: 10.1093/rheumatology/keab445 URL
[20]	Friedman MA, Winthrop KL. Vaccines and disease-modi-fying antirheumatic drugs: practical implications for the rheumatologist[J]. Rheum Dis Clin North Am, 2017, 43(1):1-13. doi: 10.1016/j.rdc.2016.09.003 URL
[21]	Medeiros-Ribeiro AC, Bonfiglioli KR, Domiciano DS, et al. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis[J]. Ann Rheum Dis, 2022, 81(5):710-719. doi: 10.1136/annrheumdis-2021-221735 pmid: 35135832
[22]	Li J, Li J, Yu Y, et al. Pneumocystis pneumonia and rheumatic disease: diagnostic potential of circulating microbial cell-free DNA sequencing[J]. Rheumatol Adv Pract, 2021, 6(1):rkab105.
[23]	Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermato-logy clinical practice[J]. Autoimmun Rev, 2015, 14(6):503-509. doi: 10.1016/j.autrev.2015.01.011 URL
[24]	Galli M, Antinori S, Atzeni F, et al. Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis[J]. Clin Exp Rheumatol, 2017, 35(6):1018-1028.
[25]	Sun F, Chen Y, Wu W, et al. Varicella zoster virus infections increase the risk of disease flares in patients with SLE: a matched cohort study[J]. Lupus Sci Med, 2019, 6(1):e000339. doi: 10.1136/lupus-2019-000339 URL

靶向治疗时代议自身免疫病的感染挑战

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王晓琳, 赵钢德, 林兰意, 周惠娟, 方跃华, 盛滋科, 蔡伟, 谢青, 丁叶舟, 陶蓉, 王晖. 戈登链球菌所致感染性心内膜炎1例[J]. 诊断学理论与实践, 2022, 21(05): 629-631.
[2]	陈宏, 沈银忠. 人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[3]	牟兴, 叶倩仪, 卢红娟, 徐沪济, 吴歆. 季节变化对风湿病发病机制及病情活动的影响[J]. 诊断学理论与实践, 2022, 21(03): 304-311.
[4]	阮玉凤, 胡丽萍, 陈史蓉, 尹君, 孙璟. 上海浦东新区全科医师对规范化诊治幽门螺杆菌感染掌握程度的调研[J]. 诊断学理论与实践, 2022, 21(03): 399-404.
[5]	张祎博, 吴文娟, 毕宇芳, 景峰, 顾志冬, 杨之涛, 尚寒冰, 林靖生, 陈尔真. 大型方舱医院感染预防与控制体系的建设和实践探索[J]. 诊断学理论与实践, 2022, 21(02): 165-168.
[6]	施莺莺, 钟旭, 刘嘉琳, 何乐, 熊少洁, 翁懿, 丁成唯, 杨溢, 陈伟红, 邱力萍, 辛海光. 新型冠状病毒疫情相关防疫工作人员感染防控实践调查分析及对策[J]. 诊断学理论与实践, 2022, 21(02): 178-183.
[7]	庄蕾, 高卫益. 新型冠状病毒肺炎疫情期间非定点医疗机构“分区管理”策略[J]. 诊断学理论与实践, 2022, 21(02): 245-247.
[8]	虞佩, 金瑞, 唐静, 陈海涛, 高卫益. 新型冠状病毒感染疫情期间非定点医疗机构急诊区域的管理策略[J]. 诊断学理论与实践, 2022, 21(02): 248-251.
[9]	王亦晨, 周剑平, 杨振华, 王敏慧, 刘佳, 倪语星, 张祎博, 石大可, 徐玉敏. 新型冠状病毒肺炎救治临时定点医院工作人员医院感染防控管理方案[J]. 诊断学理论与实践, 2022, 21(02): 270-272.
[10]	许晓倩, 卿恺, 张苏江. 造血干细胞移植后非感染性肺部并发症的诊治进展[J]. 诊断学理论与实践, 2021, 20(06): 515-521.
[11]	陆弘逾, 顾俊, 王静, 曹亚峰, 宋陆茜, 范俊, 陈梅. 干燥综合征继发隐球菌性脑膜脑炎一例报告及相关自身免疫病文献复习[J]. 诊断学理论与实践, 2021, 20(05): 456-461.
[12]	郭静, 沈银忠. HIV感染/AIDS合并结核病的临床及免疫学特点研究进展[J]. 诊断学理论与实践, 2021, 20(04): 401-406.
[13]	徐玉敏, 周惠娟, 蔡伟, 周宏洁, 王晖, 谢青. 基于PDCA循环理论的教学流程重组在感染教学中心培训管理中的实践[J]. 诊断学理论与实践, 2021, 20(03): 308-310.
[14]	孔娜娜, 张培燕, 杨德平, 金慧敏, 郑江花. 上海周浦地区2016年至2020年尿路感染者病原体分布情况及耐药性检测[J]. 诊断学理论与实践, 2021, 20(01): 93-97.
[15]	胡颖, 包玉洁, 白玉盘, 陆观珠, 成亚娇, 郭竹英, 许洁. 67例成人EB病毒感染临床及实验室特征分析[J]. 诊断学理论与实践, 2020, 19(1): 74-79.